DrMugeloveskidneys retweeted
Adenoviral disease post renal transplant
- Incidence 4 to 6%
- 75% cases within first 3 months
- Differentiate infection vs diseases
- Serial quantitative PCRs - important
- Reduction of immunosupression mainstay of treatment
- Cidofovir in severe cases
#Nephtwitter
DrMugeloveskidneys retweeted
SÍNDROME METABÓLICO DE PESO NORMAL
¡¡¡A leer, zagales!!!
Link en mi bio
o
waltersport.com/investigacio…
DrMugeloveskidneys retweeted
Time in Target Range for Hemoglobin A1c and Systolic Blood Pressure: Association With Adverse Kidney Events
bit.ly/4wIbHOR
DrMugeloveskidneys retweeted
🔺Diabetic foot disease (Nature 2026)
doi.org/10.1038/s41572-026-0…
DrMugeloveskidneys retweeted
Dialysis troubleshooting series-part 3
Cramps during dialysis - not just about hemodynamics
DrMugeloveskidneys retweeted
💊 Phosphate binders in CKD: Calcium-based or calcium-free?
The choice goes beyond serum phosphate—consider calcium load, vascular calcification, GI tolerance and pill burden.
#NephTwitter #FOAMed #MedTwitter #CKDMBD
DrMugeloveskidneys retweeted
Finerenone versus Steroidal MRAs in Type 2 Diabetes and Chronic Kidney Disease without Prior Heart Failure
Finerenone was associated with a lower 18-month risk of all-cause death compared with steroidal MRAs in patients aged ≥18 years with T2D and CKD without prior HF, who received an SGLT2 inhibitor as first-line therapy; however, residual confounding cannot be excluded, and these findings should be considered hypothesis-generating.
@mvaduganathan @gcfmd @SJGreene_md @AndrewJSauer @hfcollaboratory
academic.oup.com/eschf/advan…
DrMugeloveskidneys retweeted
La hipotensión intradialítica tiene muchas etiologías, no siempre es exceso de ultrafiltrado; antes de solo suspenderla y pasar volumen, proponen este interesante algoritmo diagnóstico y terapéutico
CKJ 2026
academic.oup.com/ndt/advance…
DrMugeloveskidneys retweeted
Atrial fibrillation in chronic kidney disease - treatment standard
doi.org/10.1093/ndt/gfag263
DrMugeloveskidneys retweeted
Efficacy of empagliflozin in heart failure with preserved ejection fraction according to the presence of echocardiographic features of diastolic dysfunction in the EMPEROR-Preserved trial
Baseline detection of echocardiographic DD predicted improved clinical response to empagliflozin in a graded fashion, but the reasons cannot be reliably determined from this analysis
@HFA_President @EJHFEiC @ehj_ed @hfcollaboratory @gcfmd @SJGreene_md @mvaduganathan
academic.oup.com/eurjhf/adva…
DrMugeloveskidneys retweeted
Initiation of Apixaban Versus Warfarin in Patients With Kidney Failure on Hemodialysis With Newly Diagnosed Atrial Fibrillation: A Target Trial Emulation
bit.ly/4yWE5NI
@winkeldoc @MontezRath @LParkerGregg1 @Khairallah_P @taraichang

ALT Time to Discontinuation among Persons who Initiated Apixaban versus Warfarin. Note: Apixaban users (in red) and warfarin users (in blue) had filled their first apixaban/warfarin prescription within 30 days from their new diagnosis with atrial fibrillation. Continued use was present when a subsequent apixaban/warfarin prescription was filled within no more than 7 days after the most recent supply was exhausted. If no refill occurred, 7 days were added to the most recent days’ supply. Apixaban/warfarin use also ended when a prescription for a different OAC was filled. We used the Aalen-Johnson estimator to graph the cumulative incidence function for both exposure groups
DrMugeloveskidneys retweeted
Short-term survival of dual SGLT2i-MRA and four-class guideline-directed medical therapy in acute heart failure
After AHF, early initiation of dual SGLT2i and MRA therapy was associated with lower short-term mortality, irrespective of LVEF or potassium levels
@hfcollaboratory @HFA_President @HFSA @DrMarthaGulati @hvanspall @gcfmd @SJGreene_md
academic.oup.com/eurjhf/adva…
DrMugeloveskidneys retweeted
Mediterranean diet and cancer risk: Current understanding and epidemiological evidence
Open Access
doi.org/10.59717/j.xinn-nutr…
#TIC2026 #nutrition #meded #medx
DrMugeloveskidneys retweeted
REVIEW: Intrarenal Determinants of GFR Decline During Loop Diuretic Therapy
ahajrnls.org/4eySKHu
















































